Bausch And Lomb Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAUSCH AND LOMB, and when can generic versions of BAUSCH AND LOMB drugs launch?
BAUSCH AND LOMB has eighty-two approved drugs.
There are forty-nine US patents protecting BAUSCH AND LOMB drugs.
There are four hundred and seventy-one patent family members on BAUSCH AND LOMB drugs in forty-seven countries and eighty supplementary protection certificates in fifteen countries.
Summary for Bausch And Lomb
| International Patents: | 471 |
| US Patents: | 49 |
| Tradenames: | 75 |
| Ingredients: | 58 |
| NDAs: | 82 |
Drugs and US Patents for Bausch And Lomb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 9,447,077 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | 9,636,332 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bausch And Lomb | OPCON | naphazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 087506-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 11,058,677 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 7,928,122 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | 8,636,713 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bausch And Lomb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | 6,426,335 | ⤷ Try a Trial |
| Bausch And Lomb | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020583-001 | Mar 9, 1998 | 5,747,061*PED | ⤷ Try a Trial |
| Bausch And Lomb | PROLENSA | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 203168-001 | Apr 5, 2013 | 8,871,813 | ⤷ Try a Trial |
| Bausch And Lomb | PROLENSA | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 203168-001 | Apr 5, 2013 | 8,669,290 | ⤷ Try a Trial |
| Bausch And Lomb | RETISERT | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 021737-001 | Apr 8, 2005 | 6,217,895 | ⤷ Try a Trial |
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | 6,211,233 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
| ➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
International Patents for Bausch And Lomb Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6373867 | ⤷ Try a Trial |
| European Patent Office | 2136812 | ⤷ Try a Trial |
| Japan | 2020127766 | ⤷ Try a Trial |
| Japan | 2007513081 | ⤷ Try a Trial |
| Singapore | 10201702674P | ⤷ Try a Trial |
| Spain | 2704125 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bausch And Lomb Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0694547 | 03C0003 | France | ⤷ Try a Trial | PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920 |
| 1280520 | CA 2015 00017 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720 |
| 0206283 | C980016 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 |
| 0509752 | 2000C/001 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306 |
| 2826776 | 2021C/517 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SYMKEVI - TEZACAFTOR/IVACAFTOR; EEN COMBINATIE VAN (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OF EEN VANUIT FARMACEUTISCH OOGPUNT GESCHIKT ZOUT DAARVAN EN (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OF EEN VANUIT FARMACEUTISCH OOGPUNT GESCHIKT ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1306 20181106 |
| 1429780 | 13C0012 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
